Please use this identifier to cite or link to this item: https://doi.org/10.1126/sciadv.aaw6071
Title: A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer
Authors: Ni, Q 
Zhang, F
Liu, Y
Wang, Z
Yu, G
Liang, B
Niu, G
Su, T
Zhu, G
Lu, G
Zhang, L
Chen, X
Keywords: Adjuvants, Immunologic
Animals
Antigen Presentation
Antigens, Neoplasm
Antineoplastic Agents, Immunological
Cancer Vaccines
Colorectal Neoplasms
Combined Modality Therapy
Dendritic Cells
Disease Models, Animal
Humans
Immunogenicity, Vaccine
Immunotherapy
Mice
Nanoparticles
Nanotechnology
Programmed Cell Death 1 Receptor
T-Lymphocytes
Theranostic Nanomedicine
Xenograft Model Antitumor Assays
Issue Date: 1-Jan-2020
Publisher: American Association for the Advancement of Science (AAAS)
Citation: Ni, Q, Zhang, F, Liu, Y, Wang, Z, Yu, G, Liang, B, Niu, G, Su, T, Zhu, G, Lu, G, Zhang, L, Chen, X (2020-01-01). A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer. Science Advances 6 (12) : eaaw6071-. ScholarBank@NUS Repository. https://doi.org/10.1126/sciadv.aaw6071
Abstract: Neoantigen vaccines have been enthusiastically pursued for personalized cancer immunotherapy while vast majority of neoantigens have no or low immunogenicity. Here, a bi-adjuvant neoantigen nanovaccine (banNV) that codelivered a peptide neoantigen (Adpgk) with two adjuvants [Toll-like receptor (TLR) 7/8 agonist R848 and TLR9 agonist CpG] was developed for potent cancer immunotherapy. Specifically, banNVs were prepared by a nano-templated synthesis of concatemer CpG, nanocondensation with cationic polypeptides, and then physical loading with hydrophobic R848 and Adpgk. The immunogenicity of the neoantigen was profoundly potentiated by efficient codelivery of neoantigen and dual synergistic adjuvants, which is accompanied by reduced acute systemic toxicity. BanNVs sensitized immune checkpoint programmed death receptor 1 (PD-1) on T cells, therefore, a combination of banNVs with aPD-1 conspicuously induced the therapy response and led to complete regression of 70% neoantigen-specific tumors without recurrence. We conclude that banNVs are promising to optimize personalized therapeutic neoantigen vaccines for cancer immunotherapy.
Source Title: Science Advances
URI: https://scholarbank.nus.edu.sg/handle/10635/234937
ISSN: 2375-2548
DOI: 10.1126/sciadv.aaw6071
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.pdf1.1 MBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

94
checked on Jan 26, 2023

Page view(s)

21
checked on Jan 26, 2023

Download(s)

1
checked on Jan 26, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.